Forte BioSciences Stock Surges After $2.2 Billion Acquisition Deal with Argenx
Forte Biosciences (FBRX) stock surged on July 27, 2026, following the announcement of a definitive agreement for Dutch immunology company Argenx (ARGX) to acquire it in an all-cash deal valued at $2.2 billion. The transaction values FBRX shares at $77 each, representing a significant 40% increase from their previous close and pushing the stock above 3.5 times its price at the start of the year. The acquisition is driven by Argenx's interest in Forte’s lead asset, FB102—a first-in-class monoclonal antibody with promising clinical results for conditions like vitiligo and celiac disease. Phase 2 readouts are expected later this year, and the drug shows potential for broader autoimmune applications such as alopecia areata. The deal is set to close in Q3 2026 and faces minimal risk due to its all-cash structure and board approval from both companies. Analysts previously had a 'Strong Buy' rating on FBRX with an average price target of $68, making the current valuation notably higher than pre-acquisition expectations.
Topics: clinical trials immunology pharmaceuticals stock movement